ASCO26: Michael Hassett, MD, MPH, eSyM - Poll - MDSpire

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

  • July 1, 2026

Share

Original Source(s)

ASCO26: Michael Hassett, MD, MPH, eSyM

  • July 1, 2026

Related Content

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min
Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome

Multimodal imaging features of primary breast epithelial–myoepithelial carcinoma: a case report and literature review